SeaStar Medical Holding Corpora
ICU
Positions held
Your positionsICU isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $18.36M | Enterprise value | $8.55M | Trailing P/E | — | Forward P/E | -1.36 |
| PEG | — | Price / book | 3.46 | Beta | -1.07 | Dividend yield | 0.00% |
| Revenue growth | 82.0% | Earnings growth | — | Gross margin | 92.6% | Operating margin | -6.2% |
| Profit margin | 0.0% | ROE | -3.6% | ROA | -102.7% | Debt / equity | 0.03 |
| Current ratio | 1.89 | Free cash flow | -$9.14M | Analyst recommendation | none | Mean target | $10.00 |
| 52w high | $7.35 | 52w low | $2.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | $0.5M | $0.4M | $0.2M | $0.3M | — |
| Op margin | -616.4% | -727.9% | -718.1% | -1955.7% | -519.5% | — |
| Net income | -$3.7M | -$3.5M | -$2.9M | -$3.5M | -$2.0M | — |
| Gross margin | 91.2% | 90.7% | 97.1% | 92.3% | 92.0% | — |
| Gross profit | $0.6M | $0.4M | $0.4M | $0.2M | $0.3M | — |
| Operating income | -$3.8M | -$3.6M | -$3.0M | -$3.6M | -$1.8M | — |
- Revenue +24% vs prior quarter ($0.6M vs $0.5M).
- Gross margin 91.2% (was 90.7% prior quarter).
- Operating margin expanded to -616.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $0.1M | $0.0M | $0.0M | — |
| Op margin | -986.6% | -13216.3% | — | — | — |
| Net income | -$12.2M | -$24.8M | -$26.2M | -$12.2M | — |
| Gross margin | 95.7% | 100.0% | — | — | — |
| Gross profit | $1.2M | $0.1M | $0.0M | — | — |
| Operating income | -$12.2M | -$17.8M | -$14.2M | -$11.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Top Midday Decliners
2026-10-05 · SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
2026-10-02 · SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
2026-10-01 · New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
2026-09-10 · SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
2026-08-17 · ICU: Continued Revenue Growth for QUELIMMUNE®
2026-08-13 · SeaStar Medical Holding Corp (ICU) (Q2 2026) Earnings Call Highlights: Qualimmune Revenue ...
2026-08-13 · SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript
2026-08-12 · SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Price (daily)
Full chart · RSI · MACD · patterns